cell-therapy-clinical-microbiology-congress-2018-keynote

3 / 6

S e p t e m b e r 1 0 - 1 1 , 2 0 1 8 | D u b l i n , I r e l a n d
Cell and Gene Therapy 2018 & Clinical Microbiology Congress 2018
Note:
Page 8
alliedacademies
CLINICAL AND MEDICAL MICROBIOLOGY
CELL AND GENE THERAPY
&
World Congress on
International Conference on
Joint Event on
Biomedical Research | ISSN: 0976-1683 | Volume 29
Shirley O’Dea, Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C3-006
IN VIVO ENGRAFTMENT OF T CELLS
TRANSFECTED USING SOLUPORE®
IS SUPERIOR COMPARED WITH
ELECTROPORATION-BASED SYSTEMS
Solupore is a vector-free intracellular delivery platform that enables
development and manufacture of cell therapies. Membrane disruption-
based methods, such as Solupore®, that enable intracellular delivery of various
cargotypesforclinicalapplicationshavebeenproposedasattractivecandidates
as next-generation delivery modalities because of potential benefits for safety,
regulation and production. Electroporation is the most widely used method
currently, this includes electroporation-based methods such as nucleofection,
however disadvantages include toxicity and proliferation stalling. Solupore®
uses reversible permeabilization to achieve rapid intracellular delivery of
cargos with varying compositions, properties and sizes. A permeabilizing
delivery solution containing a low level of ethanol is used as the permeabilizing
agent. The technology achieves intracellular delivery and subsequent reversal
of cell permeabilization by precisely controlling the contact of the target cells
with this solution. The process is rapid and cargo transfers directly into the
cytoplasm by diffusion in an endocytic-independent manner. We have termed
the method soluporation. Comparisons of the phenotype and functionality
of primary human T cells following soluporation (Solupore®), nucleofection
(4D-NucleofectorTM) and electroporation (Neon®) are outlined in this work. The
extent to which the transfection systems perturb T cells was investigated as
well as the effects on cell functionality. The results presented demonstrate that
the Solupore® technology does not perturb gene expression or cell surface
markers in T cells. Furthermore, cell proliferation and in vivo engraftment is
superior in soluporated cells compared with nucleofected cells. Thus, the
Solupore technology is gentle yet highly reproducible, automated, and scalable
and has the potential to enable a broad range of T cell engineering applications.
Biography
Shirley O’Dea has co-founded Avectas Ltd., in 2012
and is the company’s CSO. She is charged with
overseeing scientific programs. Her basic research
provides a strong pipeline of applications for Av-
ectas technology. She has previously served as a
Principal Investigator with Johnson and Johnson
and has led a large academic group specializing
in Lung Biology at National University of Ireland,
Maynooth.
Shirley O’Dea
Avectas Ltd., Ireland